Evidence map›Paper›PMID 28267593›Full record

Trial reportBiology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation2017

Phase II Study of Yttrium-90 Ibritumomab Tiuxetan Plus High-Dose BCNU, Etoposide, Cytarabine, and Melphalan for Non-Hodgkin Lymphoma: The Role of Histology.

Amrita Y Krishnan, Joycelynne Palmer, Auayporn P Nademanee, Robert Chen, Leslie L Popplewell, Ni-Chun Tsai, James F Sanchez, Jennifer Simpson, Ricardo Spielberger, Dave Yamauchi and 1 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Amrita Y KrishnanJudy and Bernard Briskin Center for Multiple Myeloma Research, City of Hope, Duarte, California; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California. Electronic address: akrishnan@coh.org.
Joycelynne PalmerDepartment of Information Sciences, City of Hope, Duarte, California.
Auayporn P NademaneeDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Robert ChenDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Leslie L PopplewellDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Ni-Chun TsaiDepartment of Information Sciences, City of Hope, Duarte, California.
James F SanchezDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
Jennifer SimpsonClinical Trials Office, City of Hope, Duarte, California.
Ricardo SpielbergerDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California; Southern California Kaiser Permanente Bone Marrow Transplant Program, Los Angeles, California.
Dave YamauchiDepartment of Diagnostic Radiology, City of Hope, Duarte, California.
Stephen J FormanDepartment of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California.
City of Hope · USKaiser Permanente · US

Funding

Transgenic Mouse FacilityP30CA033572 · NCI · CITY OF HOPE/BECKMAN RESEARCH INSTITUTE · PI XIWEI WU · 1985 to 2026
$86.3M
NCI NIH HHS P30 CA033572
6 · The paper itself

Abstract

Standard-dose

Indexed as

AdultAgedAntibodies, MonoclonalAntigens, CD20Antineoplastic Combined Chemotherapy ProtocolsCarmustineCytarabineEtoposideFemaleHistological TechniquesHumansLymphoma, Non-HodgkinMaleMelphalanMiddle AgedRemission InductionAntibodies, MonoclonalAntigens, CD20CarmustineCytarabineEtoposideibritumomab tiuxetanMelphalan(90)yttrium-ibritumomab tiuxetanAutologous stem cell transplantationBEAMRadioimmunotherapyZevalin

Identifiers

PMID28267593
PMCPMC5646666
OpenAlexW2593264636

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.